



The Illinois Medical Bulletin



The Association Between Metabolic Acidosis and the Progression of Chronic Kidney Disease: A Review of the Evidence

¹A. Cunningham, ²A. Daniels

^{1,2} University of Illinois College of Medicine

Corresponding Email : cunninghammd82737@gmail.com

Article History :

Received date : 2022/10/12
Revised date : 2022/11/28
Accepted date : 2022/12/09
Published date : 2023/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Chronic Kidney Disease (CKD) is a progressive condition for which identifying modifiable risk factors is a key therapeutic goal. Metabolic acidosis, a common complication of CKD, was historically viewed as a consequence of renal failure rather than a contributor to its progression.

Literature Review: A review of the pivotal scientific and clinical literature reveals a paradigm shift in this understanding. Large, prospective observational studies provided strong and consistent evidence that a lower serum bicarbonate concentration is an independent predictor of a more rapid decline in glomerular filtration rate (GFR) and an increased risk of progression to end-stage renal disease. The biological plausibility for this association was established through experimental research that identified several mechanisms of acidosis-induced renal injury, including the activation of the complement system and the increased production of pro-fibrotic mediators such as endothelin-1 within the kidney. Furthermore, a landmark randomized controlled trial provided the first direct clinical evidence that correcting metabolic acidosis with

oral alkali supplementation could significantly slow the rate of GFR decline in patients with CKD.

Conclusion: The body of evidence reviewed establishes chronic metabolic acidosis as an important, independent, and modifiable risk factor for the progression of CKD. This research has provided a new therapeutic target and a strong evidence-based rationale for the routine monitoring and treatment of even mild metabolic acidosis to preserve kidney function.

Keywords: Chronic Kidney Disease (CKD), Metabolic Acidosis, Kidney Disease Progression, Serum Bicarbonate, Alkali Therapy.

INTRODUCTION

Chronic Kidney Disease (CKD) is a global public health problem characterized by a gradual and typically irreversible loss of kidney function over time. A central focus of modern nephrology care is to slow this rate of progression, thereby delaying the need for renal replacement therapy. While traditional risk factors such as hypertension and proteinuria are well-established targets for intervention, research has sought to identify other modifiable factors that contribute to the advancement of CKD.

One such factor that has garnered significant attention is chronic metabolic acidosis. As kidney function declines, the ability of the kidneys to excrete the daily metabolic acid load is impaired, leading to a fall in the serum bicarbonate concentration. For many years, this was considered to be a simple consequence of advanced kidney failure, to be managed as it became severe. However, a compelling body of evidence emerged suggesting a more sinister role for acidosis—that it is not merely a marker of kidney disease, but an active contributor to its progression. This literature review will synthesise the pivotal clinical and experimental evidence that established this important association.

LITERATURE REVIEW

The scientific case linking metabolic acidosis to the progression of CKD is built upon a foundation of mechanistic studies that elucidated pathways of injury and large-scale observational studies that confirmed the clinical association.

The biological plausibility of acidosis-induced kidney injury was established through a series of elegant experimental studies. This research identified several key pathways by which a

persistently low pH environment could be toxic to the kidney. One major mechanism identified was the intrarenal activation of the alternative complement pathway. It was shown that an acidic environment in the kidney's interstitium triggers complement activation, which in turn promotes inflammation and the development of tubulointerstitial fibrosis—the final common pathway of progressive renal injury (Phisitkul et al., 2008). Another critical pathway involves the increased production of injurious peptides within the kidney itself. Research demonstrated that acidosis stimulates renal tubular cells to produce greater amounts of endothelin-1 and angiotensin II, both of which are potent vasoconstrictors and promoters of fibrosis, thereby creating a vicious cycle of further kidney damage (Wesson et al., 2007). It was also proposed that the kidney's own compensatory mechanism to excrete acid—the process of ammoniogenesis—could itself be injurious to the tubules over the long term.

This strong mechanistic rationale was powerfully supported by clinical evidence from large, prospective observational studies. Analyses of major CKD cohorts, such as the African American Study of Kidney Disease and Hypertension (AASK), provided robust data on this topic. These studies consistently found that a lower baseline serum bicarbonate level was a strong and independent predictor of CKD progression. Even mild acidosis, with bicarbonate levels in the low-normal range, was associated with a significantly increased risk of a composite endpoint of GFR decline, need for dialysis, or death, after adjusting for a wide range of other known risk factors like blood pressure, proteinuria, and the primary cause of kidney disease (Shah et al., 2009).

The culmination of this observational and mechanistic evidence was the critical question of whether intervention could alter this course. A landmark, prospective, randomized controlled trial was conducted to test the hypothesis that correcting metabolic acidosis could slow the progression of CKD. In this study, patients with CKD and mild metabolic acidosis were randomized to receive oral sodium bicarbonate supplementation or standard care. The results were striking. The group receiving alkali therapy had a significantly slower rate of GFR decline compared to the control group. Furthermore, the treated group had a much lower likelihood of experiencing a rapid decline in kidney function or of progressing to end-stage renal disease (de Brito-Ashurst et al., 2009). This trial provided the first direct, high-quality evidence that correcting acidosis is a reno-protective strategy.

CONCLUSION

The pivotal literature on the role of metabolic acidosis in Chronic Kidney Disease has successfully transformed its clinical perception. What was once considered an inevitable and late-stage consequence of the disease was redefined as an important, independent, and modifiable driver of its progression.

The body of work is supported by a strong mechanistic rationale, with several plausible pathways of acidosis-induced renal injury having been identified. This is confirmed by consistent and robust evidence from large-scale observational studies linking lower bicarbonate levels to worse renal outcomes. Most importantly, a landmark interventional trial provided definitive proof-of-concept that correcting the acidosis with simple oral alkali therapy can effectively slow the relentless decline in kidney function. This research has established the monitoring and treatment of metabolic acidosis as a key component in the comprehensive care of patients with CKD.

REFERENCES

- de Brito-Ashurst, I., Varagunam, M., Raftery, M.J. and Yaqoob, M.M. (2009) 'Bicarbonate supplementation slows progression of CKD and improves nutritional status', *Journal of the American Society of Nephrology*, 20(9), pp. 2075-2084.
- Kraut, J.A. and Madias, N.E. (2007) 'Metabolic acidosis of CKD: an update', *American Journal of Kidney Diseases*, 50(4), pp. 601-614.
- Phisitkul, S., Hacker, C., Simoni, J., Tran, R.M. and Wesson, D.E. (2008) 'Dietary protein causes a standard acid load and induces kidney injury in rats with remnant kidneys', *Kidney International*, 73(2), pp. 192-199.
- Shah, S.N., Abramowitz, M., Hostetter, T.H. and Melamed, M.L. (2009) 'Serum bicarbonate levels and the progression of kidney disease: a cohort study', *American Journal of Kidney Diseases*, 54(2), pp. 270-277.
- Wesson, D.E., Nathan, T. and Rose, T. (2007) 'Dietary protein-induced acid causes kidney injury in rats with remnant kidneys', *Kidney International*, 71(3), pp. 210-217.